[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354594-105":59,"doc-detail-354594-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","uterine-serous-carcinoma-and-germline-genetic-testing-patterns-of-referral-completion-and-pathogenic-variant-detection","Uterine serous carcinoma and germline genetic testing - patterns of referral, completion and pathogenic variant detection","","Guidelines recommend germline genetic testing for patients with uterine serous carcinoma (USC), yet real-world evidence remains limited regarding testing completion and pathogenic variant (PV) detection. This retrospective study reviewed USC cases diagnosed from 2019 to 2024 at a single academic cancer centre, assessing referral rates, completion, PV prevalence, and determinants of referral and completion. Among 131 patients, only a subset was referred, and PVs were detected in cancer genes after completion.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/uterine-serous-carcinoma-and-germline-genetic-testing-patterns-of-referral-completion-and-pathogenic-variant-detection/354594/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/uterine-serous-carcinoma-and-germline-genetic-testing-patterns-of-referral-completion-and-pathogenic-variant-detection/354594.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does this study address about USC and germline genetic testing?","Question",{"text":112,"@type":113},"It evaluates referral and completion rates for germline genetic testing in patients with uterine serous carcinoma, estimates the prevalence of clinically meaningful pathogenic variants, and examines factors associated with referral and completion.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients were included and what proportion were referred or completed testing?",{"text":117,"@type":113},"Of 131 individuals, prior genetic testing was rare, and only 45 were recommended to undergo genetic testing or referred to cancer genetics; completion occurred in a subset of those recommended.",{"name":119,"@type":110,"acceptedAnswer":120},"Which findings relate to pathogenic variant detection and associated predictors?",{"text":121,"@type":113},"Pathogenic variants were identified in a proportion of individuals who completed germline testing, and a personal history of cancer other than USC was independently associated with discovering a pathogenic variant.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354594,1790182144,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer genetics  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1136/jmg-2025-111285](10.1136/jmg-2025-111285)) .  \n1Department of Obstetrics & Gynecology, Stanford University, Palo Alto, California, USA 2Department of Pediatrics (Medical Genetics), Stanford University, Palo Alto, California, USA  \n3Cancer Genetics, Stanford Health Care, Palo Alto, California, USA  \n4Department of Medicine (Oncology), Stanford University, Palo Alto, California, USA 5Department of Epidemiology and Population Health, Stanford University, Palo Alto, California, USA  \nCorrespondence to  \nDr Talayeh S Ghezelayagh; [tghezel@stanford.edu](tghezel@stanford.edu)  \nReceived 10 October 2025 Accepted 16 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nTo cite: Tostrud L, Turkmen SB, Zhang J, et al. J Med Genet Epub ahead of print: [please include Day Month Year] . doi:10 . 1136/ jmg-2025-111285  \nOriginal research  \nUterine serous carcinoma and germline genetic testing: patterns of referral, completion and pathogenic variant detection  \nLauren Tostrud, 1 Simge Bagci Turkmen, 1 Jiaqi Zhang, 1 Rachel Hodan  ,2,3 Kerry Kingham,2,3 Oliver Dorigo, 1 James M Ford,2,3,4 Allison W Kurian,4,5  \nTalayeh S Ghezelayagh  1  \nABSTRACT  \nBackground Current guidelines recommend consideration of germline genetic testing for patients with uterine serous carcinoma (USC) but real-world data are limited on completion rates of testing and pathogenic variant (PV) identification. This study aimed to evaluate the rate of genetic testing referral and completion in a cohort of patients with USC, determine the prevalence of clinically meaningful PVs found on testing and explore factors associated with genetics referral and testing completion.  \nMethods We retrospectively examined the medical records of all individuals diagnosed with USC between 2019 and 2024 seen at a single academic cancer centre. Outcomes of interest included referral for germline genetic testing, completion of testing and testing results. Results Of 131 individuals included, 5 (3 .8%) had prior genetic testing and only 45 (34 .4%) were recommended to undergo genetic testing or referred to cancer genetics. Younger individuals and those with a personal history of cancer other than USC or family history of breast or ovarian cancer were more likely to be referred. Nine (26 . 5%) of 34 individuals who completed germline testing had a PV identified in a cancer-related gene, including BRCA1, BRCA2, BRIP1, CHEK2, MSH6, PMS2 and ATM. Only a personal history of cancer other than USC was independently associated with the discovery of a PV on germline genetic testing. In those without a prior personal history of cancer, the PV prevalence was 5.6% . Conclusions Given the high prevalence of PVs in this population, germline genetic testing for all patients diagnosed with USC can provide clinically meaningful benefit but is currently underused in practice.  \nINTRODUCTION  \nIn 2022, the most recent global estimates suggest that endometrial cancer accounted for 420 242 new cases worldwide and 97 704 deaths.1 Global burden analyses show that incident cases have risen substantially over recent decades (from ~1 87 191 in 1990 to ~4 35 041 in 2019).2 Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer—representing only 10% of cases but responsible for 40% of endometrial cancer-related deaths.3  \nAccumulating data suggest an increased risk of USC in individuals with hereditary cancer  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Both the incidence and mortality of uterine cancer are rising in the USA. There is an increasing understanding of associations between germline pathogenic variants and uterine serous carcinoma (USC) but data are limited.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ ","cbCaitmDD7GIirjC","https://ap.wps.com/l/cbCaitmDD7GIirjC","pdf",489165,"English","# ABSTRACT\n## Background\n## Methods\n## Results\n## Conclusions\n# INTRODUCTION\n## Burden of endometrial cancer and USC\n# WHAT IS ALREADY KNOWN ON THIS TOPIC\n# WHAT THIS STUDY ADDS\n# HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY","[{\"question\":\"What question does this study address about USC and germline genetic testing?\",\"answer\":\"It evaluates referral and completion rates for germline genetic testing in patients with uterine serous carcinoma, estimates the prevalence of clinically meaningful pathogenic variants, and examines factors associated with referral and completion.\"},{\"question\":\"How many patients were included and what proportion were referred or completed testing?\",\"answer\":\"Of 131 individuals, prior genetic testing was rare, and only 45 were recommended to undergo genetic testing or referred to cancer genetics; completion occurred in a subset of those recommended.\"},{\"question\":\"Which findings relate to pathogenic variant detection and associated predictors?\",\"answer\":\"Pathogenic variants were identified in a proportion of individuals who completed germline testing, and a personal history of cancer other than USC was independently associated with discovering a pathogenic variant.\"}]","Uterine serous carcinoma and germline genetic testing - patterns of referral, completion and pathogenic variant detection | PDF",1790112368,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de6be955fe416abc39f7271900900187.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25ff2eb33cb053ae732ba43f2a3e6033.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/099c626cbcf838427ca967e710591b90.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99a56433ccca78495bfeb8a59ba32662.webp",980,1306]